Population pharmacokinetics of cefepime in neonates with severe nosocomial infections

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 3, 2008, Pages 295-306

  Lima Rogel, V ^a,c   Medina Rojas, E L ^b   Del Carmen Milan Segovia R ^b   Noyola, D E ^a   Nieto Aguirre, K ^a   Lopez Delarosa A ^a   Romano Moreno, S ^b  

^a HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

Cefepime; Neonates; Non linear mixed effect model; Population pharmacokinetics

Indexed keywords

CEFEPIME;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; DEMOGRAPHY; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INTERMITTENT THERAPY; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFANT; NEWBORN; NEWBORN INFECTION; NONHUMAN; NONLINEAR SYSTEM; PSEUDOMONAS; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS INFECTION; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; MALE; MEXICO; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS;

EID: 43049134816     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00913.x     Document Type: Article

References (32)

1. Mangues BM, Trocóniz IF, Soy Muner D, Moreira da Silva R, Alba AG, Ginovart GG (2001) Análisis farmacocinético poblacional de gentamicina en neonatos. Farmacia Hospitalaria, 25, 284 292.
2. Rodriguez-Weber MA, Lopez-Candiani C, Arredondo-Garcia JL et al. (2003) Neonatal sepsis morbidity and mortality in a tertiary care hospital. Salud Publica de Mexico, 45, 90 95.
3. Silva J, Gatica R, Aguilar C et al. (2001) Outbreak of infection with extended-spectrum β-lactamase-producing Klebsiella penumoniae in a Mexican hospital. Journal of Clinical Microbiology, 39, 3193 3196.
4. Gonzalez-Vertiz A, Alcantar-Curiel D, Cuauhtli M et al. (2001) Multirresistant extended-spectrum-β-lactamase-producing Klebsiella pneumoniae causing an outbreak of nosocomial bloodstream infection. Infection Control and Hospital Epidemiology, 22, 723 725.
5. Barradell L, Bryson H (1994) Cefepime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 47, 471 505.
6. Cárdenas E, Escolar M, Honorato J (2001) Farmacología de cefepima. Emergencias, 13, S57 S62.
7. Garrelts J, Wagner D (1999) The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. Annals of Pharmacotherapy, 33, 1258 1261.
8. Burgess D, Hastings R, Hardin T (2000) Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clinical Therapeutics, 22, 66 75.
9. Okamoto MP, Nakahiro RK, Chin A et al. (1993) Cefepime clinical pharmacokinetics. Clinical Pharmacokinetics, 25, 88 102.
10. Sáez-LIorens X, Castaño E, García R et al. (1995) Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrobial Agents and Chemotherapy, 39, 937 940.
11. Blumer JL, Reed MD, Knupp C (2001) Review of the pharmacokinetics of cefepime in children. Pediatric Infectious Disease Journal, 20, 337 342.
12. Reed M, Toyooko SY, Knupp CK et al. (1997) Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrobial Agents and Chemotherapy, 41, 1783 1787.
13. Capparelli E, Hochwald C, Rasmussen M et al. (2005) Population pharmacokinetics of cefepime in the neonate. Antimicrobial Agents and Chemotherapy, 49, 2760 2766.
14. Bristol-Myers Squibb Company (2003) Maxipime (cefepime hydrochloride) for injection. Princeton, NJ : Bristol-Myers Squibb Company (package insert).
15. Beal SL, Sheiner LB (1992) NONMEM user's guides. San Francisco, CA : NONMEM Project Group, University of California.
16. ®: a manual of drugs used in neonatal care, 17th edn. Raleigh, NC : Acorn Publishing, 14 15.
17. Elkhaili H, Linger L, Monteil H et al. (1997) High-performance liquid chromatographic assay for cefepime in serum. Journal of Chromatography. B, Biomedical Sciences and Applications, 690, 181 188.
18. Mejía R (2004) Implementación y validación de un método analítico para cuantificar cefepime en plasma por cromatografía de líquidos de alta resolución. Tesis de licenciatura de Químico Farmacobiólogo, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí. México! San Luis Potosí.
19. Secretaría de Salud Norma Oficial Mexicana NOM-177-SSA1-1998 (1998) Que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los terceros autorizados que realicen las pruebas. Diario Oficial de la Federación. México : D.F., México.
20. Jonsson EN, Karlsson MO (1999) Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods and Programs in Biomedicine, 58, 51 64.
21. Mosteller RD (1987) Simplified calculation of body-surface area. New England Journal of Medicine, 317, 1098.
22. Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatric Nephrology, 34, 571 590.
23. Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5, 445 479.
24. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503 512.
25. Vozeh S, Maitre PO, Stanki DR (1990) Evaluation of population (NONMEM) pharmacokinetic parameter estimates. Journal of Pharmacokinetics and Biopharmaceutics, 18, 161.
26. Grasela TH (1986) Population pharmacokinetics: application to clinical trials. In : Smith RB, Kroboth PD, Juhl RP, eds. Pharmacokinetics and pharmacodynamics. Research design and analysis. Cincinnati : Harvey Witney Books. 85 103.
27. Lee P (2001) Design and power of a population pharmacokinetic study. Pharmaceutical Research, 18, 75 82.
28. Koren G (1997) Therapeutic drug monitoring principles in the neonate. Clinical Chemistry, 43, 222 227.
29. Peters AM, Henderson BL, Lui D (2000) Indexed glomerular filtration rate as a function of age and body size. Clinical Science, 98, 439 444.
30. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases, 26, 1 12.
31. National Committee for Clinical Laboratory Standards (NCCLS) (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. Wayne, PA : NCCLS.
32. Ambrose P, Owens R, Garvey M et al. (2002) Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. Journal of Antimicrobial Chemotherapy, 49, 445 453.